MoonLake Immunotherapeutics
MLTX · NASDAQ
Financial statements
Annual and quarterly income, balance-sheet, cash-flow and key-statistics data.
Income statement
| Period | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2022 FY | — | — | -65.06M | -49.97M | -2.20 |
| 2023 FY | — | — | -54.12M | -36.01M | -0.73 |
| 2024 FY | — | — | -143.09M | -118.94M | -1.89 |
| 2025 FY | — | -2.62M | -244.83M | -227.32M | -3.53 |
Balance sheet
| Period | Total assets | Liabilities | Cash | Debt | Equity |
|---|---|---|---|---|---|
| 2022 FY | 76.84M | 8.08M | 39.51M | 282.58K | 48.90M |
| 2023 FY | 526.54M | 13.05M | 451.17M | 3.70M | 495.68M |
| 2024 FY | 477.93M | 24.54M | 180.43M | 2.83M | 446.83M |
| 2025 FY | 424.43M | 119.95M | 334.52M | 75.71M | 304.48M |
Cash flow
| Period | Operating cash flow | Capital expenditure | Free cash flow | Dividends paid | Net cash change |
|---|---|---|---|---|---|
| 2022 FY | -55.89M | -16.01K | -55.91M | — | 31.47M |
| 2023 FY | -42.78M | -284.63K | -43.06M | — | 411.66M |
| 2024 FY | -116.59M | -519.52K | -117.11M | — | -270.74M |
| 2025 FY | -196.01M | -35.00K | -196.04M | — | 154.09M |
Key statistics
| Period | Market cap | Enterprise value | P/E | Price / sales | Debt / equity |
|---|---|---|---|---|---|
| 2022 FY | 308.29M | 269.07M | — | — | — |
| 2023 FY | 2.97B | 2.52B | — | — | — |
| 2024 FY | 3.40B | 3.23B | — | — | — |
| 2025 FY | 849.63M | 590.83M | — | — | — |
Income statement
| Period | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2025 Q2 | — | -742.00K | -60.70M | -55.22M | -0.87 |
| 2025 Q3 | — | — | -71.43M | -69.73M | -1.10 |
| 2025 Q4 | — | -751.00K | -65.22M | -62.43M | -0.93 |
| 2026 Q1 | — | -845.00K | -70.02M | -69.71M | -0.98 |
Balance sheet
| Period | Total assets | Liabilities | Cash | Debt | Equity |
|---|---|---|---|---|---|
| 2025 Q2 | 460.10M | 102.15M | 306.68M | 75.77M | 353.73M |
| 2025 Q3 | 414.34M | 123.14M | 350.74M | 75.73M | 288.91M |
| 2025 Q4 | 424.43M | 119.95M | 334.52M | 75.71M | 304.48M |
| 2026 Q1 | 400.37M | 146.35M | 298.49M | 100.80M | 254.02M |
Cash flow
| Period | Operating cash flow | Capital expenditure | Free cash flow | Dividends paid | Net cash change |
|---|---|---|---|---|---|
| 2025 Q2 | -54.53M | — | -54.53M | — | 35.12M |
| 2025 Q3 | -44.54M | — | -44.54M | — | 44.06M |
| 2025 Q4 | -58.79M | — | -58.79M | — | -16.22M |
| 2026 Q1 | -66.29M | — | -66.29M | — | -36.03M |
Key statistics
| Period | Market cap | Enterprise value | P/E | Price / sales | Debt / equity |
|---|---|---|---|---|---|
| 2025 Q2 | 2.99B | 2.76B | — | — | — |
| 2025 Q3 | 454.36M | 179.35M | — | — | — |
| 2025 Q4 | 849.63M | 590.83M | — | — | — |
| 2026 Q1 | 1.33B | 1.13B | — | — | — |